{"id":958449,"date":"2026-05-05T17:28:32","date_gmt":"2026-05-05T21:28:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-reports-first-quarter-2026-financial-results-and-provides-business-update\/"},"modified":"2026-05-05T17:28:32","modified_gmt":"2026-05-05T21:28:32","slug":"cytokinetics-reports-first-quarter-2026-financial-results-and-provides-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-reports-first-quarter-2026-financial-results-and-provides-business-update\/","title":{"rendered":"Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update"},"content":{"rendered":"
\n

\n U.S. Launch of MYQORZO<\/em>
\n
\n \u00ae<\/em>
\n <\/sup>
\n (aficamten) in Late January Met with Strong Demand; <\/em>
\n
\n Over 275 HCPs Prescribed MYQORZO to an estimated 680 Patients in Q1<\/em>\n <\/p>\n

\n ACACIA-HCM Met Dual Primary Endpoints of KCCQ and Maximal Exercise Performance; <\/em>
\n
\n Full Results to be Presented at Upcoming Medical Congress<\/em>\n <\/p>\n

\n MYQORZO Approved by the European Commission for Adults with Symptomatic Obstructive HCM;
Supplemental NDA for MAPLE-HCM Accepted for Filing by FDA with PDUFA Date of November 14, 2026<\/em>\n <\/p>\n

\n Net Product Revenues for MYQORZO of $4.8 Million for Initial Partial Quarter;<\/em>
\n
\n ~$1.1 Billion in Cash, Cash Equivalents and Investments as of March 31, 2026<\/em>\n <\/p>\n

SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) reported a management update and financial results for the first quarter of 2026.<\/p>\n

\u201cThe U.S. launch of MYQORZO commenced strongly in late January and continues to accelerate. We promptly activated a solid prescriber base of early adopters and are encouraged by initial commercial metrics that are exceeding our expectations,\u201d said Robert I. Blum, Cytokinetics\u2019 President and Chief Executive Officer. \u201cIn addition, today we shared positive topline results from ACACIA-HCM in non-obstructive HCM showing that aficamten<\/em> improved both symptoms and maximal exercise performance, a milestone achievement that opens the aperture for aficamten<\/em> to potentially address the entire spectrum of HCM. We look forward to building on our strong start and driving meaningful progress for both the commercial launch of MYQORZO and the continued advancement of our pipeline.\u201d<\/p>\n

\n Q1 and Recent Highlights <\/strong>\n <\/p>\n

\n
\n Cardiac Muscle Programs<\/u>
\n <\/strong>\n <\/p>\n

\n MYQORZO<\/strong>
\n
\n \u00ae<\/strong>
\n <\/sup>
\n (<\/strong>
\n
\n aficamten<\/em>
\n <\/strong>
\n )<\/strong> (cardiac myosin inhibitor)<\/p>\n